Skip to main content

Advertisement

Table 4 Association between ZIC2 immunostaining results and prostate cancer phenotype in tissue micro-arrayed cancers

From: Random forest-based modelling to detect biomarkers for prostate cancer progression

Parameter n evaluable Negative (%) Positive (%) p value Bonferroni correction
All cancers 12,581 76.7 23.3   
Tumour stage
 pT2 7994 74.6 25.4 < 0.0001 0.000006
 pT3a 2837 78.7 21.3 0.000018
 pT3b-pT4 1700 83.1 16.9 0.000029
Gleason grade
 ≤ 3 + 3 2303 71.5 28.5 < 0.0001 0.000022
 3 + 4 6700 75.1 24.9 0.000007
 3 + 4 Tert.5 606 77.7 22.3 0.000083
 4 + 3 1238 81.4 18.6 0.000040
 4 + 3 Tert.5 907 85.6 14.4 0.000055
 ≥ 4 + 4 731 87.1 12.9 0.000068
Lymph node metastasis
 N0 7459 77.6 22.4 < 0.0001 0.000007
 N+ 932 86.3 13.7 0.000054
Preop. PSA level (ng/ml)
 < 4 1479 75.8 24.2 < 0.0001 0.000034
 4–10 7470 75.4 24.6 0.000007
 10–20 2642 79.2 20.8 0.000019
 > 20 916 81.3 18.7 0.000055
Surgical margin
 Negative 10,018 75.8 24.2 < 0.0001 0.000005
 Positive 2519 80.3 19.7 0.000020